TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.J Microbiol Immunol Infect. 2020 Jun; 53(3):368-370.JM
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.